Ephx2 Deficiency Reduces COPD by Targeting Ferroptosis Mechanism

Chronic obstructive pulmonary disease (COPD) contributes to over 3 million deaths annually worldwide, highlighting a significant public health challenge. Despite existing therapies, there remain unmet needs for effective treatments that mitigate disease progression and related morbidity.

This study employs a preclinical model to investigate the effects of genetic deletion of Ephx2 on COPD mechanisms induced by cigarette smoke exposure. The research utilizes a multicenter design with animal subjects to elucidate the role of ferroptosis in lung injury and inflammation associated with COPD.

Ephx2 deficiency led to a notable reduction in COPD-like symptoms, showing a 30% decrease in lung inflammation and a 25% improvement in pulmonary function compared to control groups. Additionally, ferroptosis markers were significantly altered, indicating a protective effect against oxidative stress-induced lung damage.

These findings support the potential for targeting the ferroptosis pathway as an innovative therapeutic strategy for COPD, especially in genetically susceptible populations. However, the study is limited by its preclinical nature and necessitates further validation in human trials to assess generalizability.

Original citation address: https://www.besjournal.com/en/article/doi/10.3967/bes2026.012